Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

Rhea-AI Summary

Jupiter Neurosciences (NASDAQ: JUNS) entered an Omnibus Amendment with YA II PN, Ltd. that defers installment repayments to April 1, 2026 while keeping the $6.0 million core economic financing terms unchanged. The amendment modifies timing and application mechanics only and adds no new pricing, resets, or commitments.

Management says the change aligns capital timing with advancing its Phase II Parkinson’s program and scaling commercial sales of Nugevia (JOTROL resveratrol), which shows ~25% repeat purchases and ~3% returns. The company remains in compliance with its transaction documents.

Positive

• Repayment deferred to April 1, 2026
• Core financing economics unchanged at $6.0 million
• Nugevia showing ~25% repeat purchase rate

Negative

• Amendment does not provide additional financing or new capital
• Installment schedule still requires future principal repayments

News Market Reaction – JUNS

+0.02%

1 alert

+0.02% News Effect

+$4K Valuation Impact

$19M Market Cap

0.0x Rel. Volume

On the day this news was published, JUNS gained 0.02%, reflecting a mild positive market reaction. This price movement added approximately $4K to the company's valuation, bringing the market cap to $19M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Financing size: $6.0 million Repayment start date: April 1, 2026 Phase II program: Phase II +2 more

5 metrics

Financing size $6.0 million Core economic terms of financing referenced as unchanged

Repayment start date April 1, 2026 Deferred commencement of monthly installment payments

Phase II program Phase II Advancement of Parkinson’s disease program

Repeat purchase rate 25 percent Approximate repeat purchase activity for Nugevia™ ecommerce sales

Product return rate 3 percent Approximate return rate reported for Nugevia™ products

Market Reality Check

Price: $0.5200 Vol: Volume 31,720 reflects a ...

low vol

$0.5200 Last Close

Volume Volume 31,720 reflects a relative volume of 0.05 vs the 20-day average, indicating light trading activity ahead of this amendment. low

Technical Shares trade at 0.5199, below the 200-day MA of 1.2, reflecting a longer-term downtrend into this news.

Peers on Argus

JUNS fell 6.64% while peers showed mixed moves: several names like BTAI and SER ...

JUNS fell 6.64% while peers showed mixed moves: several names like BTAI and SER were down, but MAIA gained 2.46%. No peers appeared on the momentum scanner, suggesting the move was more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Product positioning update	Positive	-23.5%	Expanded Nugevia™ focus to GLP‑1 users and longevity positioning.
Jan 27	Conference participation	Neutral	-0.0%	Announcement of company presentation at DealFlow Discovery Conference.
Dec 23	Investor webinar	Positive	-2.7%	Webinar on JOTROL™, Nugevia™ strategy, and upcoming Phase 2a trial.
Dec 03	Year-in-review update	Positive	+2.5%	Milestone recap including IND clearance and Nugevia™ launch with Yorkville financing.
Dec 02	Conference participation	Neutral	-1.7%	Participation in NobleCon21 with investor meeting availability.

Pattern Detected

Recent news with positive or strategic tone has often seen muted or negative next-day moves, indicating a tendency toward divergence between narrative and short-term price action.

Recent Company History

Over the past several months, Jupiter has focused on financing flexibility and dual-path execution. In October 2025 it secured a Yorkville agreement for up to $20 million and pre-paid advances up to $6.0 million. A December 2025 update highlighted FDA-cleared Phase 2a Parkinson’s plans and Nugevia™ launches, with a 2.54% gain. However, later promotional and positioning updates around Nugevia™ and conferences in December 2025–January 2026 coincided with negative or flat reactions, including a -23.53% move on a GLP‑1‑focused expansion, framing today’s amendment within a history of cautious market responses.

Market Pulse Summary

This announcement centered on an Omnibus Amendment that defers monthly installments on the Yorkville...

Analysis

This announcement centered on an Omnibus Amendment that defers monthly installments on the Yorkville notes to April 1, 2026 while keeping the core $6.0 million financing economics intact. Management highlighted focus on the Phase II Parkinson’s program and Nugevia™ commercialization, citing about 25% repeat purchases and roughly 3% returns as early indicators. Against a backdrop of prior financing agreements and mixed market responses to strategic news, investors may monitor future filings and clinical milestones to assess execution and funding balance.

Key Terms

convertible promissory notes, standby equity purchase agreement, phase ii, neuroinflammation, +2 more

6 terms

convertible promissory notes financial

"modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued"

A convertible promissory note is a loan a company takes that can later be turned into shares instead of being paid back in cash; think of lending money now in exchange for a voucher that can become ownership later. Investors care because it mixes credit risk and potential ownership upside—it can protect lenders if a company struggles while also diluting existing shareholders when converted, affecting future share value and investor returns.

standby equity purchase agreement financial

"notes issued under the Company’s Standby Equity Purchase Agreement"

A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.

phase ii medical

"advancing our Phase II Parkinson’s program while continuing to scale Nugevia™"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

neuroinflammation medical

"a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

central nervous system medical

"focused on neuroinflammation and central nervous system disorders"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

resveratrol medical

"Nugevia™, its patented JOTROL™-based resveratrol platform"

A naturally occurring plant compound found in grapes, berries and some nuts, resveratrol is often studied for potential health effects such as heart and cellular protection. Investors watch it because positive research or regulatory approvals can boost demand for supplements, attract biotech or pharmaceutical development, and affect companies that sell health products — think of it as a small ingredient that can change the value of whole product lines if proven effective.

AI-generated analysis. Not financial advice.

Repayment Commencement Deferred to April 1, 2026

Core Economic Terms of $6.0 Million Financing Remain Unchanged

JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company’s Standby Equity Purchase Agreement.

Under the amendment:

• Monthly installment payments will now begin on April 1, 2026
• Principal repayments will follow a defined schedule agreed between the Company and Yorkville
  
  

The amendment does not introduce any new pricing provisions, reset features or additional financing commitments. The amendment relates solely to installment timing and application mechanics and does not alter the underlying economic terms of the financing.

“This amendment reflects a deliberate and aligned decision between Jupiter and Yorkville,” said Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences. “Yorkville demonstrated its commitment to our long-term strategy by adjusting installment timing without changing pricing, maturity or other economic terms. That alignment enables us to remain focused on advancing our Phase II Parkinson’s program while continuing to scale Nugevia^™ and build commercial cash flow.”

Jupiter’s strategy combines clinical development with active commercial revenue generation. In addition to advancing its neuroinflammation pipeline, the Company is generating revenue through Nugevia^™, its patented JOTROL^™-based resveratrol platform. Current ecommerce sales reflect repeat purchase activity of approximately 25 percent and product return rates of approximately 3 percent. Management believes this early commercial validation, alongside continued clinical progress, strengthens Jupiter’s capital profile and differentiates the Company from biotechnology peers that rely solely on capital markets funding.

The Company remains in compliance with its obligations under the Transaction Documents.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The Company’s lead clinical program is advancing through a Phase IIa trial in Parkinson’s disease. Jupiter is also commercializing Nugevia^™, a consumer product built on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability. Jupiter’s dual-path strategy combines clinical development with commercial revenue generation.

For more information, visit www.jupiterneurosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described in such statements. These statements include, but are not limited to, statements regarding clinical development, commercialization plans, revenue growth, capital planning, and future operating performance. Factors that could cause actual results to differ materially include clinical trial outcomes, regulatory developments, market acceptance of Nugevia, capital market conditions, Nasdaq listing requirements, and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Investor Contact
Jupiter Neurosciences, Inc.
1001 North US Highway 1, Suite 504
Jupiter, FL 33477
Email: ir@jupiterneurosciences.com

FAQ

What change did Jupiter Neurosciences (JUNS) make to Yorkville installment payments on Feb 23, 2026?

The company deferred monthly installment payments to April 1, 2026 to align cash timing. According to the company, the amendment modifies only timing and application mechanics and does not change pricing, maturity, or core economic terms.

Does the Omnibus Amendment change the $6.0 million financing terms for JUNS?

No — the amendment keeps the $6.0 million core economics unchanged while altering installment timing. According to the company, no new pricing provisions, resets, or additional financing commitments were introduced.

How does the amendment affect Jupiter’s clinical and commercial plans for JUNS?

It aims to align capital timing with clinical and commercial execution to preserve runway. According to the company, this enables focus on its Phase II Parkinson’s program and scaling Nugevia commercial sales.

What commercial traction does Nugevia show in Jupiter’s update for JUNS?

Nugevia ecommerce sales show approximately 25% repeat purchase activity and about 3% product returns. According to the company, management views this as early commercial validation supporting the capital profile.

Will Yorkville provide additional financing under the amendment for JUNS?

No — the amendment does not create additional financing commitments or reset pricing. According to the company, the change only adjusts installment timing and application mechanics without new funding promises.